Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

ClinicalTrials.gov ID: NCT07095127

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07095127. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Study identification

NCT ID: NCT07095127
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Nuvig Therapeutics, Inc.; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Immune Thrombocytopenia (ITP)

Interventions

NVG-2089 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2025 (Actual)
Primary completion: Jun 30, 2027 (Estimated)
Completion: Dec 31, 2027 (Estimated)
Last update posted: Sep 14, 2026

2025 – 2027

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	Recruiting
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	Recruiting
East Carolina University	Greenville	North Carolina	27834	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07095127, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 14, 2026 · Synced Nov 15, 2026